How liver drug transport proteins are controlled by tyrosine kinases
Regulation of hepatic uptake transporters by tyrosine kinases
This project looks at how enzymes called tyrosine kinases change a liver drug-uptake protein (OATP1B1) and how that can alter medicine levels and side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11176821 on NIH RePORTER |
What this research studies
You will hear about lab work that aims to find which kinases control the liver transporter OATP1B1 and how those changes affect drug handling. Scientists will use biochemical tests, cell-based experiments, and animal models to map the specific kinase modifications and measure effects on drug uptake. They will also study how blocking those kinases changes blood drug levels and responses, to model drug-drug interactions. The work is meant to clarify why some drug combinations unexpectedly raise drug levels and cause serious side effects like statin-related muscle injury.
Who could benefit from this research
Good fit: People taking medications known to be cleared by OATP1B1 (for example certain statins and other drugs) or those interested in future clinical pharmacokinetic studies would be the most relevant candidates.
Not a fit: Patients whose treatments are not cleared by liver uptake transporters or who need immediate clinical therapy changes are unlikely to get direct benefit from this basic/translational research.
Why it matters
Potential benefit: If successful, this research could help predict or prevent dangerous drug-drug interactions and improve the safety of medicines cleared by OATP1B1.
How similar studies have performed: Prior work has linked OATP1B1 genetic differences to altered drug levels and statin toxicity, and some drug-drug interactions have been documented, but the specific regulation of OATP1B1 by kinases is relatively underexplored.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Sprowl, Jason a — State University of New York at Buffalo
- Study coordinator: Sprowl, Jason a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.